

Pilot Collaborations with LMICs in Global Cancer Research or Global Health Research at NCI-Designated Cancer Centers

LEIDOS BIOMED SUBCONTRACT FINAL SCIENTIFIC PROGRESS REPORT

OMB No.: 0925-XXXX

Expiration Date: xx/xx/20xx

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Rights of study participants are protected by The Privacy Act of 1974. Participation is voluntary, and there are no penalties for not participating or withdrawing from the study at any time. Refusal to participate will not affect your benefits in any way. The information collected in this study will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the study. Information provided will be combined for all study participants and reported as summaries. You are being contacted by email to complete this instrument so that we can improve future workshops.

Public reporting burden for this collection of information is estimated to average 240 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-XXXX). Do not return the completed form to this address.

Project Title:

Organization Name and Address:

Subcontract #: _____

Report Preparation Date: _____

Reporting Period Covered: _____
(i.e., 2/1/14- 4/31/14)

Name of Person Submitting Report: _____

Email Address: _____

Phone Number: _____

Partner Organizations/Collaborators:

(please include country)

Pilot Collaborations with LMICs in Global Cancer Research or Global Health Research at NCI-Designated Cancer Centers

LEIDOS BIOMED SUBCONTRACT FINAL SCIENTIFIC PROGRESS REPORT

1. Please provide a brief description of the topic(s) being addressed in your project. (e.g. evaluation of a cancer detection tool; one paragraph maximum)
2. Please provide a brief description of accomplishments against the objectives outlined in your award.

Objective	Accomplishments

3. Please provide a brief description of barriers/challenges that you encountered while working on your objectives, along with how you plan to address them for the next reporting period.

Barrier/Challenge	Plans to Address

4. Please provide a brief summary/justification of the budget utilization during this performance period, which may include activities such as: proportion of budget spent, need for investment in infrastructure and/or capacity building, anticipated spending in the forthcoming period.
5. Please provide any pertinent feedback obtained from your partner site(s) this reporting period.
6. Principal Investigator's Overview (please limit this to 3 pages using a minimum of 11 point font single space)

We ask that you provide an overview of the partnership and the pilot project at the conclusion of the subcontract period of performance. In communicating these activities and scientific progress, please be sure to address the following considerations should they apply to you:

- a. Provide a list of all resources that were generated as a result of this project (e.g., patents, software design, research materials such as but not limited to cell lines, microarrays, DNA probes).
- b. If the project included a clinical trial, provide a status of patient/specimen accrual.
- c. If the project included the development or improvements to biobanks, biospositories, tumor banks, or cancer registries, provide a brief description of the benefits and/or impact to the LMIC investigator, institution, or country.
- d. List any publications or pending manuscripts.
- e. Describe any future plans for continuing this project as a result of this collaboration.
- f. Describe any new research collaborations or opportunities that arose as a result of this project.